Statins in depression: a repurposed medical treatment can provide novel insights in mental health

References

• Abbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015). Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders, 183, 149–155. https://doi.org/10.1016/j.jad.2015.04.049
   PubMed Web of Science ®Google Scholar
• Al-Asmari, A. K., Ullah, Z., Al Masoudi, A. S., & Ahmad, I. (2017). Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. Journal of Experimental Pharmacology, ume 9, 47–57. https://doi.org/10.2147/JEP.S128696
   Google Scholar
• Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018). Risk of neuropsychiatric adverse effects of lipid-lowering drugs: A mendelian randomization study. International Journal of Neuropsychopharmacology, 21(12), 1067–1075. https://doi.org/10.1093/ijnp/pyy060
   PubMed Web of Science ®Google Scholar
• Arns, M., van Dijk, H., Luykx, J. J., van Wingen, G., & Olbrich, S. (2022). Stratified psychiatry: Tomorrow's precision psychiatry? European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 55, 14–19. https://doi.org/10.1016/j.euroneuro.2021.10.863
   PubMed Web of Science ®Google Scholar
• Avan, R., Sahebnasagh, A., Hashemi, J., Monajati, M., Faramarzi, F., Henney, N. C., Montecucco, F., Jamialahmadi, T., & Sahebkar, A. (2021). Update on statin treatment in patients with neuropsychiatric disorders. Life, 11(12), 1365. https://doi.org/10.3390/life11121365
   PubMedGoogle Scholar
• Avrahamy, H., Shoval, G., Hoshen, M., Balicer, R. D., Kamhi-Nesher, S., Zalsman, G., Weizman, A., & Krivoy, A. (2021). Association between adherence to SSRI treatment and mortality among individuals with metabolic syndrome components. Pharmacopsychiatry, 54(05), 232–239. https://doi.org/10.1055/a-1425-7246
   PubMed Web of Science ®Google Scholar
• Bartoli, F., Cavaleri, D., Bachi, B., Moretti, F., Riboldi, I., Crocamo, C., & Carrà, G. (2021). Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials. Journal of Psychiatric Research, 143, 230–238. https://doi.org/10.1016/j.jpsychires.2021.09.018
   PubMed Web of Science ®Google Scholar
• Bartoli, F., Crocamo, C., Dakanalis, A., Riboldi, I., Miotto, A., Brosio, E., Clerici, M., & Carrà, G. (2017). Association between total serum cholesterol and suicide attempts in subjects with major depressive disorder: Exploring the role of clinical and biochemical confounding factors. Clinical Biochemistry, 50(6), 274–278. https://doi.org/10.1016/j.clinbiochem.2016.11.035
   PubMed Web of Science ®Google Scholar
• Bartoli, F., Di Brita, C., Crocamo, C., Clerici, M., & Carrà, G. (2017). Lipid profile and suicide attempt in bipolar disorder: A meta-analysis of published and unpublished data. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 79(Pt B), 90–95. https://doi.org/10.1016/j.pnpbp.2017.06.008
   PubMedGoogle Scholar
• Berk, M., & Nierenberg, A. A. (2015). Three paths to drug discovery in psychiatry. The American Journal of Psychiatry, 172(5), 412–414. https://doi.org/10.1176/appi.ajp.2014.14070858
   PubMed Web of Science ®Google Scholar
• Berk, M., Mohebbi, M., Dean, O. M., Cotton, S. M., Chanen, A. M., Dodd, S., Ratheesh, A., Amminger, G. P., Phelan, M., Weller, A., Mackinnon, A., Giorlando, F., Baird, S., Incerti, L., Brodie, R. E., Ferguson, N. O., Rice, S., Schäfer, M. R., Mullen, E., … Davey, C. G. (2020). Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): A randomised clinical trial of rosuvastatin and aspirin. BMC Medicine, 18(1), 16. https://doi.org/10.1186/s12916-019-1475-6
   PubMed Web of Science ®Google Scholar
• Bhattarai, B., Swamy, S., Baral, S. R., & Acharya, C. P. (2017). A study on the effect of atorvastatin on the pharmacokinetic and antidepressant activity of fluoxetine. National Journal of Physiology, Pharmacy and Pharmacology, 7(11), 1–1229. https://doi.org/10.5455/njppp.2017.7.0622519072017
   Google Scholar
• Binder, L. B., Ludka, F. K., Cunha, M. P., Dal-Cim, T., Constantino, L. C., Massari, C., Martins, W. C., Rodrigues, A. L. S., & Tasca, C. I. (2015). Atorvastatin prevents cell death and depressive-like behaviour induced by Abeta1-40 peptide via BDNF cleavage. Journal of Neurochemistry, 134(SUPPL. 1), 332–333. https://doi.org/10.1111/jnc.13189
   Google Scholar
• Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016). Cognitive remission: A novel objective for the treatment of major depression? BMC Medicine, 14, 9. https://doi.org/10.1186/s12916-016-0560-3
   PubMed Web of Science ®Google Scholar
• Bot, M., Milaneschi, Y., Al-Shehri, T., Amin, N., Garmaeva, S., Onderwater, G. L., Pool, R., Thesing, C. S., Vijfhuizen, L. S., Vogelzangs, N., Arts, I. C., Demirkan, A., van Duijn, C., van Greevenbroek, M., van der Kallen, C. J., Köhler, S., Ligthart, L., van den Maagdenberg, A. M., Mook-Kanamori, D. O., … Sattar, N. (2020). Metabolomics profile in depression: A pooled analysis of 230 metabolic markers in 5283 cases with depression and 10,145 controls. Biological Psychiatry. 87(5), 409–418. https://doi.org/10.1016/j.biopsych.2019.08.016
   PubMed Web of Science ®Google Scholar
• Can, Ö. D., Ulupinar, E., Özkay, Ü. D., Yegin, B., & Öztürk, Y. (2012). The effect of simvastatin treatment on behavioral parameters, cognitive performance, and hippocampal morphology in rats fed a standard or a high-fat diet. Behavioural Pharmacology, 23(5–6), 582–592. https://doi.org/10.1097/FBP.0b013e328356c3f2
   PubMed Web of Science ®Google Scholar
• Caspani, G., Turecki, G., Lam, R. W., Milev, R. V., Frey, B. N., MacQueen, G. M., Müller, D. J., Rotzinger, S., Kennedy, S. H., Foster, J. A., & Swann, J. R. (2021). Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. Communications Biology, 4(1), 903. https://doi.org/10.1038/s42003-021-02421-6
   PubMed Web of Science ®Google Scholar
• Chavez-Castillo, M., Nava, M., Ortega, A., Rojas, M., Nunez, V., Salazar, J., Bermudez, V., & Rojas-Quintero, J. (2020). Depression as an immunometabolic disorder: Exploring shared pharma-cotherapeutics with cardiovascular disease. Current Neuropharmacology, 18(11), 1138–1153. https://doi.org/10.2174/1570159X18666200413144401
   PubMed Web of Science ®Google Scholar
• Ciccocioppo, R. (2017). Grand challenge in psychopharmacology: Setting priorities to shape a bright future. Frontiers in Psychiatry, 8, 15. https://doi.org/10.3389/fpsyt.2017.00015
   PubMed Web of Science ®Google Scholar
• Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
   PubMed Web of Science ®Google Scholar
• Citraro, R., Chimirri, S., Aiello, R., Gallelli, L., Trimboli, F., Britti, D., De Sarro, G., & Russo, E. (2014). Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia, 55(8), 1284–1291. https://doi.org/10.1111/epi.12686
   PubMed Web of Science ®Google Scholar
• Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., … Peto, R. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 388(10059), 2532–2561. https://doi.org/10.1016/S0140-6736(16)31357-5
   PubMed Web of Science ®Google Scholar
• Covington, H. E., Vialou, V., & Nestler, E. J. (2010). From synapse to nucleus: Novel targets for treating depression. Neuropharmacology, 58(4–5), 683–693. https://doi.org/10.1016/j.neuropharm.2009.12.004
   PubMed Web of Science ®Google Scholar
• Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92–107. https://doi.org/10.1002/wps.20701
   PubMed Web of Science ®Google Scholar
• da Cruz, J. N., Dal Magro, D. D., de Lima, D. D., & da Cruz, J. G. P. (2017). Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety: A literature review. Brazilian Journal of Pharmaceutical Sciences, 53(1), e16102. https://doi.org/10.1590/s2175-97902017000116102
   Web of Science ®Google Scholar
• De Giorgi, R., De Crescenzo, F., Cowen, P. J., Harmer, C. J., & Cipriani, A. (2022). STAT-QResearch. OSF.
   Google Scholar
• De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J. (2021). Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PLOS One, 16(3), e0249409. https://doi.org/10.1371/journal.pone.0249409
   PubMed Web of Science ®Google Scholar
• De Giorgi, R., Martens, M., Rizzo Pesci, N., Cowen, P. J., & Harmer, C. J. (2021). The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. Journal of Psychopharmacology, 35(12), 1479–1487. https://ovidsp.ovid.com/ovidweb.cgi?T = JS&CSC = Y&NEWS = N&PAGE = fulltext&D = emexb&AN=2014417489
   PubMed Web of Science ®Google Scholar
• De Giorgi, R., Quinton, A. G. M., Waters, S., Cowen, P. J., & Harmer, C. J. (2022). An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers. Psychopharmacology, 239(8), 2635–2645. https://doi.org/10.1007/s00213-022-06156-y
   PubMed Web of Science ®Google Scholar
• De Giorgi, R., Rizzo Pesci, N., Quinton, A., De Crescenzo, F., Cowen, P. J., & Harmer, C. J. (2021). Statins in depression: An evidence-based overview of mechanisms and clinical studies. Frontiers in Psychiatry, 12, 702617. https://doi.org/10.3389/fpsyt.2021.702617
   PubMed Web of Science ®Google Scholar
• De Giorgi, R., Waters, S., Pesci, N. R., Rosso, G., Cowen, P. J., & Harmer, C. J. (2022). The effects of statin monotherapy on depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 311, 336–343. https://doi.org/10.1016/j.jad.2022.05.113
   PubMed Web of Science ®Google Scholar
• Dell’Osso, B., Albert, U., Carrà, G., Pompili, M., Nanni, M. G., Pasquini, M., Poloni, N., Raballo, A., Sambataro, F., Serafini, G., Viganò, C., Demyttenaere, K., McIntyre, R. S., & Fiorillo, A. (2020). How to improve adherence to antidepressant treatments in patients with major depression: A psychoeducational consensus checklist. Annals of General Psychiatry, 19(1), 61. https://doi.org/10.1186/s12991-020-00306-2
   PubMed Web of Science ®Google Scholar
• Demyttenaere, K., & Van Duppen, Z. (2019). The impact of (the concept of) treatment-resistant depression: An opinion review. The International Journal of Neuropsychopharmacology, 22(2), 85–92. https://doi.org/10.1093/ijnp/pyy052
   PubMed Web of Science ®Google Scholar
• Detka, J., & Głombik, K. (2021). Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacological Reports, 73(4), 1020–1032. https://doi.org/10.1007/s43440-021-00274-8
   PubMed Web of Science ®Google Scholar
• Downs, J. R., Oster, G., & Santanello, N. C. (1993). HMG CoA reductase inhibitors and quality of life. JAMA, 269(24), 3107–3108. https://doi.org/10.1001/jama.269.24.3107
   PubMed Web of Science ®Google Scholar
• Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022). Immune targets for therapeutic development in depression: Towards precision medicine. Nature Reviews. Drug Discovery, 21(3), 224–244. https://doi.org/10.1038/s41573-021-00368-1
   PubMed Web of Science ®Google Scholar
• Ebada, M. E. (2017). Drug repurposing may generate novel approaches to treating depression. The Journal of Pharmacy and Pharmacology, 69(11), 1428–1436. https://doi.org/10.1111/jphp.12815
   PubMed Web of Science ®Google Scholar
• Eisel, U. L. M., Dolga, A., Granic, I., Dobos, N., Naude, P., Nyakas, C., & Luiten, P. G. M. (2010). Inflammation as a target in neurodegenerative disease and related depression. Acta Physiologica Hungarica, 97(4), 437–438. https://doi.org/10.1556/APhysiol.97.2010.4.7
   Google Scholar
• ElBatsh, M. M. (2015). Antidepressant-like effect of simvastatin in diabetic rats. Canadian Journal of Physiology and Pharmacology, 93(8), 649–656. https://doi.org/10.1139/cjpp-2014-0560
   PubMed Web of Science ®Google Scholar
• Eltokhi, A., & Sommer, I. E. (2022). A reciprocal link between gut microbiota, inflammation and depression: A place for probiotics? Frontiers in Neuroscience, 16, 852506. https://doi.org/10.3389/fnins.2022.852506
   PubMed Web of Science ®Google Scholar
• Endo, A., Kuroda, M., & Tanzawa, K. (1976). Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Letters, 72(2), 323–326. https://doi.org/10.1016/0014-5793(76)80996-9
   PubMed Web of Science ®Google Scholar
• Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P., Rujescu, D., Mendlewicz, J., De Ronchi, D., Riva, M. A., Lewis, C. M., & Serretti, A. (2021). Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 104, 110050. https://doi.org/10.1016/j.pnpbp.2020.110050
   PubMed Web of Science ®Google Scholar
• Farooqui, A. A., Ong, W. Y., Horrocks, L. A., Chen, P., & Farooqui, T. (2007). Comparison of biochemical effects of statins and fish oil in brain: The battle of the titans. Brain Research Reviews, 56(2), 443–471. https://doi.org/10.1016/j.brainresrev.2007.09.004
   PubMedGoogle Scholar
• Feng, L., Yap, K. B., Kua, E. H., & Ng, T. P. (2010). Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiology and Drug Safety, 19(9), 942–948. https://doi.org/10.1002/pds.1993
   PubMed Web of Science ®Google Scholar
• Fernandes, B. S., Williams, L. M., Steiner, J., Leboyer, M., Carvalho, A. F., & Berk, M. (2017). The new field of 'precision psychiatry. BMC Medicine, 15(1), 80. https://doi.org/10.1186/s12916-017-0849-x
   PubMedGoogle Scholar
• Fernandes, B., Dai, Y., Jia, P., & Zhao, Z. (2021). Charting the proteome landscape in major psychiatric disorders: from biomarkers to biological pathways for precision psychiatry. European Neuropsychopharmacology, 51, e171–e172. https://doi.org/10.1016/j.euroneuro.2021.08.137
   Web of Science ®Google Scholar
• Fiorillo, A., & Gorwood, P. (2020). The consequences of the COVID-19 pandemic on mental health and implications for clinical practice. European Psychiatry: The Journal of the Association of European Psychiatrists, 63(1), e32. https://doi.org/10.1192/j.eurpsy.2020.35
   PubMed Web of Science ®Google Scholar
• Fiorillo, A., & Maj, M. (2018). The role of psychiatry in modern medicine. International Review of Psychiatry, 30(2), 169–175. https://doi.org/10.1080/09540261.2018.1436675
   PubMed Web of Science ®Google Scholar
• Fiorillo, A., & Sartorius, N. (2021). Mortality gap and physical comorbidity of people with severe mental disorders: The public health scandal. Annals of General Psychiatry, 20(1), 52. https://doi.org/10.1186/s12991-021-00374-y
   PubMed Web of Science ®Google Scholar
• Fiorillo, A., Luciano, M., Pompili, M., & Sartorius, N. (2019). Editorial: Reducing the mortality gap in people with severe mental disorders: The role of lifestyle psychosocial interventions. Frontiers in Psychiatry, 10, 434. https://doi.org/10.3389/fpsyt.2019.00434
   PubMed Web of Science ®Google Scholar
• Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2019). Statins and the brain: More than lipid lowering agents? Current Neuropharmacology, 17(1), 59–83. https://doi.org/10.2174/1570159x15666170703101816
   PubMed Web of Science ®Google Scholar
• Furukawa, T. A., Shinohara, K., Sahker, E., Karyotaki, E., Miguel, C., Ciharova, M., Bockting, C. L. H., Breedvelt, J. J. F., Tajika, A., Imai, H., Ostinelli, E. G., Sakata, M., Toyomoto, R., Kishimoto, S., Ito, M., Furukawa, Y., Cipriani, A., Hollon, S. D., & Cuijpers, P. (2021). Initial treatment choices to achieve sustained response in major depression: A systematic review and network meta-analysis. World Psychiatry, 20(3), 387–396. https://doi.org/10.1002/wps.20906
   PubMed Web of Science ®Google Scholar
• Gillespie, A. L., Wigg, C., van Assche, I., Murphy, S. E., & Harmer, C. J. (2022). Associations between statin use and negative affective bias during COVID-19: An observational, longitudinal UK study investigating depression vulnerability. Biological Psychiatry, S0006-3223(22)01126-X. https://doi.org/10.1016/j.biopsych.2022.03.009
   Web of Science ®Google Scholar
• Gitsels, L. A., Bakbergenuly, I., Steel, N., & Kulinskaya, E. (2021). Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records. A Family Medicine, Public and Community Health, 9(2):e000780. https://doi.org/10.1136/fmch-2020-000780
   PubMed Web of Science ®Google Scholar
• Godlewska, B. R., & Harmer, C. J. (2021). Cognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatment. Psychopharmacology, 238(5), 1265–1278. https://doi.org/10.1007/s00213-019-05448-0
   PubMed Web of Science ®Google Scholar
• Guerreiro Costa, F. L. N., Carneiro, B. A., Alves, G. S., Lins Silva, D. H., Faria Guimaraes, D., Souza, L. S., Bandeira, I. D., Beanes, G., Miranda Scippa, A., & Quarantini, L. C. (2022). Metabolomics of major depressive disorder: A systematic review of clinical studies. Cureus, 14(3), e23009. https://doi.org/10.7759/cureus.23009
   PubMedGoogle Scholar
• Hai-Na, Z., Xu-Ben, Y., Cong-Rong, T., Yan-Cheng, C., Fan, Y., Lei-Mei, X., Ruo-Lan, S., Ye-Zi, W., Liang, J., Ye-Zi  , Ye-Xuan, W., & Jing, L. (2020). Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice. Psychopharmacology, 237(3), 695–705. https://doi.org/10.1007/s00213-019-05406-w
   PubMed Web of Science ®Google Scholar
• Hang, X., Zhang, Y., Li, J., Li, Z., Zhang, Y., Ye, X., Tang, Q., & Sun, W. (2021). Comparative efficacy and acceptability of anti-inflammatory agents on major depressive disorder: A network meta-analysis. Frontiers in Pharmacology, 12, 691200. https://doi.org/10.3389/fphar.2021.691200
   PubMed Web of Science ®Google Scholar
• Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry, 4(5), 409–418. https://doi.org/10.1016/S2215-0366(17)30015-9
   PubMed Web of Science ®Google Scholar
• Hayes, J. F., Lundin, A., Wicks, S., Lewis, G., Wong, I. C. K., Osborn, D. P. J., & Dalman, C. (2019). Association of hydroxylmethyl glutaryl coenzyme a reductase inhibitors, L-Type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry, 76(4), 382–390. https://doi.org/10.1001/jamapsychiatry.2018.3907
   PubMed Web of Science ®Google Scholar
• Hirschfeld, R. M. (2000). History and evolution of the monoamine hypothesis of depression. The Journal of Clinical Psychiatry, 61 (Suppl 6), 4–6.
   PubMed Web of Science ®Google Scholar
• Hyyppä, M. T., Kronholm, E., Virtanen, A., Leino, A., & Jula, A. (2003). Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology, 28(2), 181–194. https://doi.org/10.1016/S0306-4530(02)00014-8
   PubMed Web of Science ®Google Scholar
• Irwin, J. C., Fenning, A. S., & Vella, R. K. (2020). Statins with different lipophilic indices exert distinct effects on skeletal, cardiac and vascular smooth muscle. Life Sciences, 242, 117225. https://doi.org/10.1016/j.lfs.2019.117225
   PubMed Web of Science ®Google Scholar
• Jacka, F. N., & Berk, M. (2013). Depression, diet and exercise. The Medical Journal of Australia, 199(S6), S21–S23. https://doi.org/10.5694/mja12.10508
   PubMedGoogle Scholar
• James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R. S., Abebe, Z., Abera, S. F., Abil, O. Z., Abraha, H. N., Abu-Raddad, L. J., Abu-Rmeileh, N. M. E., Accrombessi, M. M. K., … Murray, C. J. L. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392(10159), 1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Jarończyk, M., & Walory, J. (2022). Novel molecular targets of antidepressants. Molecules, 27(2), 533. https://doi.org/10.3390/molecules27020533
   PubMed Web of Science ®Google Scholar
• Jones, B. D. M., Farooqui, S., Kloiber, S., Husain, M. O., Mulsant, B. H., & Husain, M. I. (2021). Targeting metabolic dysfunction for the treatment of mood disorders: Review of the evidence. Life, 11(8), 819. https://doi.org/10.3390/life11080819
   PubMedGoogle Scholar
• Kang, H. J., Bae, K. Y., Kim, S. W., Kim, J. T., Park, M. S., Cho, K. H., & Kim, J. M. (2016). Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up. Psychoneuroendocrinology, 72, 156–160. https://doi.org/10.1016/j.psyneuen.2016.07.001
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015). A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials, 16, 495. https://doi.org/10.1186/s13063-015-1023-4
   PubMed Web of Science ®Google Scholar
• Kessing, L. V., Rytgaard, H. C., Gerds, T. A., Berk, M., Ekstrøm, C. T., & Andersen, P. K. (2019). New drug candidates for depression – a nationwide population-based study. Acta Psychiatrica Scandinavica, 139(1), 68–77. https://doi.org/10.1111/acps.12957
   PubMed Web of Science ®Google Scholar
• Kilic, F. S., Ozatik, Y., Kaygisiz, B., Baydemir, C., & Erol, K. (2012). Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. Neurosciences, 17(1), 39–43.
   PubMed Web of Science ®Google Scholar
• Kilic, F. S., Ozatyk, Y., Kaygisiz, B., Baydemyr, C., & Erol, K. (2010). Focused Conference Group: P17 – Newapproaches and targets in psychiatry investigation of antidepressant and anxiolytic effects of simvastatine in rats. Basic and Clinical Pharmacology and Toxicology, 107(SUPPL. 1), 374. https://doi.org/10.1111/j.1742-7843.2010.00600.x
   Google Scholar
• Kim, S. W., Kang, H. J., Jhon, M., Kim, J. W., Lee, J. Y., Walker, A. J., Agustini, B., Kim, J. M., & Berk, M. (2019). Statins and inflammation: New therapeutic opportunities in psychiatry. Frontiers in Psychiatry, 10, 103. https://doi.org/10.3389/fpsyt.2019.00103
   PubMed Web of Science ®Google Scholar
• Kim, S.-W., Kang, H.-J., Bae, K.-Y., Shin, I.-S., Hong, Y. J., Ahn, Y.-K., Jeong, M. H., Berk, M., Yoon, J.-S., & Kim, J.-M. (2018). Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 80(Pt C), 250–254. https://doi.org/10.1016/j.pnpbp.2017.07.003
   PubMedGoogle Scholar
• Köhler, O., Gasse, C., Petersen, L., Ingstrup, K. G., Nierenberg, A. A., Mors, O., & Østergaard, S. D. (2016). The effect of concomitant treatment with SSRIs and statins: A population-based study. The American Journal of Psychiatry, 173(8), 807–815. https://doi.org/10.1176/appi.ajp.2016.15040463
   PubMed Web of Science ®Google Scholar
• Köhler-Forsberg, O., C, N. L., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019). Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatrica Scandinavica, 139(5), 404–419. https://doi.org/10.1111/acps.13016
   PubMed Web of Science ®Google Scholar
• Köhler-Forsberg, O., Gasse, C., Petersen, L., Nierenberg, A. A., Mors, O., & Østergaard, S. D. (2019). Statin treatment and the risk of depression. Journal of Affective Disorders, 246, 706–715. https://doi.org/10.1016/j.jad.2018.12.110
   PubMed Web of Science ®Google Scholar
• Köhler-Forsberg, O., Otte, C., Gold, S. M., & Østergaard, S. D. (2020). Statins in the treatment of depression: Hype or hope? Pharmacology & Therapeutics, 215, 107625. https://doi.org/10.1016/j.pharmthera.2020.107625
   PubMed Web of Science ®Google Scholar
• Kokkeler, K. J. E., Marijnissen, R. M., Wardenaar, K. J., Rhebergen, D., van den Brink, R. H. S., van der Mast, R. C., & Oude Voshaar, R. C. (2022). Subtyping late-life depression according to inflammatory and metabolic dysregulation: A prospective study. Psychological Medicine, 52(3), 515–525. https://doi.org/10.1017/s0033291720002159
   PubMed Web of Science ®Google Scholar
• Kosowski, M., Smolarczyk-Kosowska, J., Hachuła, M., Maligłówka, M., Basiak, M., Machnik, G., Pudlo, R., & Okopień, B. (2021). The effects of statins on neurotransmission and their neuroprotective role in neurological and psychiatric disorders. Molecules, 26(10), 2838. https://doi.org/10.3390/molecules26102838
   PubMed Web of Science ®Google Scholar
• Krivoy, A., Balicer, R. D., Feldman, B., Hoshen, M., Zalsman, G., Weizman, A., & Shoval, G. (2016). Adherence to antidepressants is associated with lower mortality: A 4-year population-based cohort study. The Journal of Clinical Psychiatry, 77(5), e566-572–e572. https://doi.org/10.4088/JCP.14m09531
   Web of Science ®Google Scholar
• Kumar, A., Vashist, A., Kumar, P., Kalonia, H., & Mishra, J. (2012). Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice. Pharmacological Reports, 64(6), 1326–1336. https://doi.org/10.1016/S1734-1140(12)70930-1
   PubMed Web of Science ®Google Scholar
• Lee, M. C., Peng, T. R., Chen, B. L., Lee, C. H., Wang, J. Y., Lai, C. P., Lee, J. A., Chen, S. M., & Shiang, J. C. (2021a). Effects of various statins on depressive symptoms: A network meta-analysis. Journal of Affective Disorders, 293, 205–213. https://doi.org/10.1016/j.jad.2021.06.034
   PubMed Web of Science ®Google Scholar
• Lee, M. C., Peng, T. R., Lee, C. H., Wang, J. Y., Lee, J. A., Chen, S. M., & Shiang, J. C. (2021b). Statin use and depression risk: A systematic review and meta-analysis. Journal of Affective Disorders, 282, 308–315. https://doi.org/10.1016/j.jad.2020.12.164
   PubMed Web of Science ®Google Scholar
• Le-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., Shekhar, A., Kurian, S. M., & Niculescu, A. B. (2021). Precision medicine for mood disorders: Objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry, 26(7), 2776–2804. doi:https://doi.org/10.1038/s41380-021-01061-w
   PubMed Web of Science ®Google Scholar
• Lesperance, F., Frasure-Smith, N., Theroux, P., & Irwin, M. (2004). The association between major depression and levels of soluble intercellular adhesion molecule 1, lnterleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. The American Journal of Psychiatry, 161(2), 271–277. doi:https://doi.org/10.1176/appi.ajp.161.2.271
   PubMed Web of Science ®Google Scholar
• Leutner, M., Matzhold, C., Kautzky, A., Kaleta, M., Thurner, S., Klimek, P., & Kautzky-Willer, A. (2021). Major Depressive Disorder (MDD) and antidepressant medication are overrepresented in high-dose statin treatment. Frontiers in Medicine, 8, 608083. https://doi.org/10.3389/fmed.2021.608083
   Web of Science ®Google Scholar
• Li, F., Ling, Z. L., Wang, Z. J., Zhong, Z. Y., Shu, N., Zhang, M., Liu, C., Liu, L., & Liu, X. D. (2017). Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 47(1), 20–30. https://doi.org/10.3109/00498254.2016.1154999
   PubMed Web of Science ®Google Scholar
• Lim, S.-W., Shiue, Y.-L., Liao, J.-C., Wee, H.-Y., Wang, C.-C., Chio, C.-C., Chang, C.-H., Hu, C.-Y., & Kuo, J.-R. (2017). Simvastatin therapy in the acute stage of traumatic brain injury attenuates brain trauma-induced depression-like behavior in rats by reducing neuroinflammation in the hippocampus. Neurocritical Care, 26(1), 122–132. https://doi.org/10.1007/s12028-016-0290-6
   PubMed Web of Science ®Google Scholar
• Lin, P.-Y., Chang, A. Y. W., & Lin, T.-K. (2014). Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress. Pharmacology, Biochemistry, and Behavior, 124, 174–179. https://doi.org/10.1016/j.pbb.2014.06.006
   PubMed Web of Science ®Google Scholar
• Ljung, R., Köster, M., Björkenstam, E., & Salmi, P. (2021). Associations between statin use and suicidality, depression, anxiety, and seizures. The Lancet. Psychiatry, 8(2), e2. https://doi.org/10.1016/s2215-0366(20)30512-5
   PubMed Web of Science ®Google Scholar
• Luciano, M., Sampogna, G., Amore, M., Andriola, I., Calcagno, P., Carmassi, C., Del Vecchio, V., Dell'Osso, L., Di Lorenzo, G., Gelao, B., Giallonardo, V., Rossi, A., Rossi, R., Siracusano, A., & Fiorillo, A. (2021). How to improve the physical health of people with severe mental illness? A multicentric randomized controlled trial on the efficacy of a lifestyle group intervention. European Psychiatry, 64(1), e72. https://doi.org/10.1192/j.eurpsy.2021.2253
   PubMed Web of Science ®Google Scholar
• Ludka, F. K., Constantino, L. C., Dal-Cim, T., Binder, L. B., Zomkowski, A., Rodrigues, A. L. S., & Tasca, C. I. (2016). Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice. Journal of Psychiatric Research, 82, 50–57. https://doi.org/10.1016/j.jpsychires.2016.07.004
   PubMed Web of Science ®Google Scholar
• Ludka, F. K., Constantino, L. C., Kuminek, G., Binder, L. B., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T., Rodrigues, A. L. S., & Tasca, C. I. (2014). Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice. Pharmacology, Biochemistry, and Behavior, 122, 253–260. https://doi.org/10.1016/J.PBB.2014.04.005
   PubMed Web of Science ®Google Scholar
• Ludka, F. K., Cunha, M. P., Dal-Cim, T., Binder, L. B., Constantino, L. C., Massari, C. M., Martins, W. C., Rodrigues, A. L. S., & Tasca, C. I. (2017a). Atorvastatin protects from Aβ1–40-induced cell damage and depressive-like behavior via ProBDNF cleavage (Vol. 54, pp.6163–6173): Springer.
   Google Scholar
• Ludka, F. K., Cunha, M. P., Dal-Cim, T., Binder, L. B., Constantino, L. C., Massari, C. M., Martins, W. C., Rodrigues, A. L. S., & Tasca, C. I. (2017b). Atorvastatin and fluoxetine prevent oxidative stress and mitochondrial dysfunction evoked by glutamate toxicity in hippocampal slices. Molecular Neurobiology, 54(8), 6163–6173. https://doi.org/10.1007/s12035-016-0134-6
   PubMedGoogle Scholar
• Ludka, F. K., Zomkowski, A. D., Cunha, M. P., Dal-Cim, T., Zeni, A. L., Rodrigues, A. L., & Tasca, C. I. (2013). Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 23(5), 400–412. https://doi.org/10.1016/j.euroneuro.2012.05.005
   PubMed Web of Science ®Google Scholar
• Ma, W., Shen, D., Liu, J., Pan, J., Yu, L., Shi, W., Deng, L., Zhu, L., Yang, F., Liu, J., Cai, W., Yang, J., Luo, Y., Cui, H., & Liu, S. (2016). Statin function as an anti-inflammation therapy for depression in patients with coronary artery disease by downregulating interleukin-1beta. Journal of Cardiovascular Pharmacology, 67(2), 129–135. https://doi.org/10.1097/FJC.0000000000000323
   PubMed Web of Science ®Google Scholar
• Maes, M., Fisar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012). New drug targets in depression: Inflammatory, cell-mediate immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. and new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 20(3), 127–150. https://doi.org/10.1007/s10787-011-0111-7
   PubMedGoogle Scholar
• Maj, M., Stein, D. J., Parker, G., Zimmerman, M., Fava, G. A., De Hert, M., Demyttenaere, K., McIntyre, R. S., Widiger, T., & Wittchen, H. U. (2020). The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry, 19(3), 269–293. https://doi.org/10.1002/wps.20771
   PubMed Web of Science ®Google Scholar
• Malhi, G. S., Bell, E., Morris, G., & Hamilton, A. (2020). The delay in response to antidepressant therapy: A window of opportunity? The Australian and New Zealand Journal of Psychiatry, 54(2), 127–129. https://doi.org/10.1177/0004867419900313
   PubMed Web of Science ®Google Scholar
• Massardo, T., Quintana, J. C., Risco, L., Corral, S., Spuler, J., Vicentini, D., Castro-Muñoz, G., Riedel, B., Villa, C., & Pereira, J. I. (2022). Effect of low-dose statins in addition to standard therapy on brain perfusion and neurocognitive performance in patients with major depressive disorder. Neuropsychobiology, 81(4), 215–271. https://doi.org/10.1159/000521104
   PubMed Web of Science ®Google Scholar
• Massardo, T., Quintana, J., Pereira, J., Saez, C., Risco, L., Corral, S., Olivares, N., Spuler, J., Castro, G., Vicentini, D., Riedel, B., Valenzuela, G., & Villa, C. (2020). Effect of statins on brain perfusion in major depression as an addition to standard therapy. SPM analysis of inflammation, platelet activation, endothelial dysfunction and neurocognitive parameters. European Journal of Nuclear Medicine and Molecular Imaging, 47(SUPPL 1), S446–S447. https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed22&AN=634255459
   Web of Science ®Google Scholar
• McFarland, A. J., Anoopkumar-Dukie, S., Arora, D. S., Grant, G. D., McDermott, C. M., Perkins, A. V., & Davey, A. K. (2014). Molecular mechanisms underlying the effects of statins in the central nervous system. International Journal of Molecular Sciences, 15(11), 20607–20637. https://doi.org/10.3390/ijms151120607
   PubMed Web of Science ®Google Scholar
• McGovern, A. S., Hamlin, A. S., & Winter, G. (2019). A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. The Australian and New Zealand Journal of Psychiatry, 53(12), 1151–1166. https://doi.org/10.1177/0004867419877954
   PubMed Web of Science ®Google Scholar
• Menze, E. T., Ezzat, H., Shawky, S., Sami, M., Selim, E. H., Ahmed, S., Maged, N., Nadeem, N., Eldash, S., & Michel, H. E. (2021). Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and Estrogen receptors' modulation. International Immunopharmacology, 95, 107582. https://doi.org/10.1016/j.intimp.2021.107582
   PubMed Web of Science ®Google Scholar
• Miller, A. H., Haroon, E., & Felger, J. C. (2017). Therapeutic implications of brain-immune interactions: Treatment in translation. Neuropsychopharmacology, 42(1), 334–359. https://doi.org/10.1038/npp.2016.167
   PubMed Web of Science ®Google Scholar
• Mohammad Sadeghi, H., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. (2021). Drug repurposing for the management of depression: Where do we stand currently? Life, 11(8), 774. https://doi.org/10.3390/life11080774
   PubMedGoogle Scholar
• Molero, Y., Cipriani, A., Larsson, H., Lichtenstein, P., D'Onofrio, B. M., & Fazel, S. (2020). Associations between statin use and suicidality, depression, anxiety, and seizures: A Swedish total-population cohort study. The Lancet. Psychiatry, 7(11), 982–990. https://doi.org/10.1016/S2215-0366(20)30311-4
   PubMed Web of Science ®Google Scholar
• Momen, N. C., Plana-Ripoll, O., Agerbo, E., Christensen, M. K., Iburg, K. M., Laursen, T. M., Mortensen, P. B., Pedersen, C. B., Prior, A., Weye, N., & McGrath, J. J. (2022). Mortality associated with mental disorders and comorbid general medical conditions. JAMA Psychiatry, 79(5), 444–453. https://doi.org/10.1001/jamapsychiatry.2022.0347
   PubMed Web of Science ®Google Scholar
• Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990). Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ, 301(6747), 309–314. https://doi.org/10.1136/bmj.301.6747.309
   PubMedGoogle Scholar
• Nestler, E. J., & Hyman, S. E. (2010). Animal models of neuropsychiatric disorders. Nature Neuroscience, 13(10), 1161–1169. https://doi.org/10.1038/nn.2647
   PubMed Web of Science ®Google Scholar
• Neurauter, G., Wirleitner, B., Laich, A., Schennach, H., Weiss, G., & Fuchs, D. (2003). Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clinical and Experimental Immunology, 131(2), 264–267. https://doi.org/10.1046/j.1365-2249.2003.02021.x
   PubMed Web of Science ®Google Scholar
• Nothdurfter, C., Tanasic, S., Di Benedetto, B., Rammes, G., Wagner, E. M., Kirmeier, T., Ganal, V., Kessler, J. S., Rein, T., Holsboer, F., & Rupprecht, R. (2010). Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology, 35(7), 1510–1519. https://doi.org/10.1038/npp.2010.20
   PubMed Web of Science ®Google Scholar
• Pasco, J. A., Jacka, F. N., Williams, L. J., Henry, M. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2010). Clinical implications of the cytokine hypothesis of depression: The association between use of statins and aspirin and the risk of major depression. Psychotherapy and Psychosomatics, 79(5), 323–325. https://doi.org/10.1159/000319530
   PubMed Web of Science ®Google Scholar
• Pellosmaa, H., & Dougall, A. L. (2016). Examining the role of statins and mood on plasma lipids and health outcomes: A systematic review. Psychosomatic Medicine, 78(3), A94. https://doi.org/10.1097/PSY.0000000000000343
   Web of Science ®Google Scholar
• Pellosmaa, H., Orsak, G., Tebbe, D., Jenney, C., Das, S., Thompson, J., Carroll, J., Feldman, M., Vecchio, M., & Dougall, A. L. (2015). Managing high cholesterol: Relationships among stress, depression, adherence and inflammatory markers. Psychosomatic Medicine, 77(3), A136. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=71869347
   PubMedGoogle Scholar
• Persons, J. E., Robinson, J. G., Coryell, W. H., Payne, M. E., & Fiedorowicz, J. G. (2016). Longitudinal study of low serum LDL cholesterol and depressive symptom onset in postmenopause. The Journal of Clinical Psychiatry, 77(02), 212–220. https://doi.org/10.4088/JCP.14m09505
   PubMedGoogle Scholar
• Qiu, W., Cai, X., Zheng, C., Qiu, S., Ke, H., & Huang, Y. (2021). Update on the relationship between depression and neuroendocrine metabolism. Frontiers in Neuroscience, 15, 728810. https://doi.org/10.3389/fnins.2021.728810
   PubMed Web of Science ®Google Scholar
• Rahola, J. G. (2012). Somatic drugs for psychiatric diseases: Aspirin or simvastatin for depression? Current Neuropharmacology, 10(2), 139–158. https://doi.org/10.2174/157015912800604533
   PubMed Web of Science ®Google Scholar
• Redlich, C., Berk, M., Williams, L. J., Sundquist, J., Sundquist, K., & Li, X. (2014). Statin use and risk of depression: A Swedish National Cohort Study. BMC Psychiatry, 14(1), 348. https://doi.org/10.1186/s12888-014-0348-y
   PubMedGoogle Scholar
• Renshaw, P. F., Parsegian, A., Yang, C. K., Novero, A., Yoon, S. J., Lyoo, I. K., Cohen, B. M., & Carlezon, W. A. Jr, (2009). Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacology, Biochemistry, and Behavior, 92(1), 88–92. https://doi.org/10.1016/j.pbb.2008.10.017
   PubMed Web of Science ®Google Scholar
• Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., & McAllister-Williams, R. H. (2022). Clinical research challenges posed by difficult-to-treat depression. Psychological Medicine, 52(3), 419–432. https://doi.org/10.1017/s0033291721004943
   PubMed Web of Science ®Google Scholar
• Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Santos, T., Baungratz, M. M., Haskel, S. P., de Lima, D. D., da Cruz, J. N., Magro, D. D. D., & da Cruz, J. G. P. (2012). Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression. Neuropsychiatric Disease and Treatment, 8, 413–422. https://doi.org/10.2147/NDT.S31714
   PubMed Web of Science ®Google Scholar
• Segatto, M., Manduca, A., Lecis, C., Rosso, P., Jozwiak, A., Swiezewska, E., Moreno, S., Trezza, V., & Pallottini, V. (2014). Simvastatin treatment highlights a new role for the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats. Neuropsychopharmacology, 39(4), 841–854. https://doi.org/10.1038/npp.2013.284
   PubMed Web of Science ®Google Scholar
• Sheets, W. J., Brooks, S. D., Chantler, P., & Frisbee, J. (2016). Interventions blunting systemic inflammation and oxidant stress improve depressive symptoms and vascular function in a model of metabolic syndrome. FASEB Journal. 30, 948. http://www.fasebj.org/content/30/1_Supplement/948.15.abstract?sid=8311572a-92b5-4c61-a93c-7deaa58e0821
   Google Scholar
• Shin, J. Y., Suls, J., & Martin, R. (2008). Are cholesterol and depression inversely related? A meta-analysis of the association between two cardiac risk factors. Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine, 36(1), 33–43. https://doi.org/10.1007/s12160-008-9045-8
   PubMed Web of Science ®Google Scholar
• Shrivastava, S., Pucadyil, T. J., Paila, Y. D., Ganguly, S., & Chattopadhyay, A. (2010). Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin 1A receptors †. Biochemistry, 49(26), 5426–5435. https://doi.org/10.1021/bi100276b
   PubMed Web of Science ®Google Scholar
• Simons, J. (2003). The $10 billion pill. Fortune, 147(1), 58–62.
   PubMedGoogle Scholar
• Sizar, O., Khare, S., Jamil, R. T., & Talati, R. (2022). Statin medications. In StatPearls. StatPearls Publishing, Copyright © 2022, StatPearls Publishing LLC.
   Google Scholar
• So, H. C., Chau, C. K., Lau, A., Wong, S. Y., & Zhao, K. (2019). Translating GWAS findings into therapies for depression and anxiety disorders: Gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. Psychological Medicine, 49(16), 2692–2708. https://doi.org/10.1017/s0033291718003641
   PubMed Web of Science ®Google Scholar
• Solmi, M., Miola, A., Croatto, G., Pigato, G., Favaro, A., Fornaro, M., Berk, M., Smith, L., Quevedo, J., Maes, M., Correll, C. U., & Carvalho, A. F. (2021). How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Revista Brasileira de Psiquiatria, 43(2), 189–202. https://doi.org/10.1590/1516-4446-2020-0935
   PubMedGoogle Scholar
• Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Archives of Neurology, 62(5), 753–757. https://ovidsp.ovid.com/ovidweb.cgi?T = JS&CSC = Y&NEWS = N&PAGE = fulltext&D = emed9&AN=40656090
   PubMedGoogle Scholar
• Tang, C.-R., Yu, X.-B., Zhang, H.-N., Cao, Y.-C., Yang, F., Xu, L.-M., Sun, R.-L., Ye, Z., Wang, Y.-X., & Liang, J. (2020). Lovastatin prevents depressive behaviors and increased hippocampal neurogenesis in streptozotocin-induced diabetic mice. Pharmacology, 105(5–6), 339–348. https://doi.org/10.1159/000503865
   PubMed Web of Science ®Google Scholar
• Tao, S. H., Ren, X. Q., Zhang, L. J., & Liu, M. Y. (2021). Association between common cardiovascular drugs and depression. Chinese Medical Journal, 134(22), 2656–2665. doi:https://doi.org/10.1097/CM9.0000000000001875
   PubMed Web of Science ®Google Scholar
• Taylor, W. D., Aizenstein, H. J., & Alexopoulos, G. S. (2013). The vascular depression hypothesis: Mechanisms linking vascular disease with depression. Molecular Psychiatry, 18(9), 963–974. https://doi.org/10.1038/mp.2013.20
   PubMed Web of Science ®Google Scholar
• Tsai, S.-J. (2007). Statins may enhance the proteolytic cleavage of proBDNF: Implications for the treatment of depression. Medical Hypotheses, 68(6), 1296–1299. https://doi.org/10.1016/j.mehy.2006.09.043
   PubMed Web of Science ®Google Scholar
• Urquhart, L. (2019). Top drugs and companies by sales in 2018. Nature Reviews Drug Discovery, 18, 245. https://doi.org/10.1038/d41573-019-00049-0
   Web of Science ®Google Scholar
• van Agtmaal, M. J. M., Houben, A., Pouwer, F., Stehouwer, C. D. A., & Schram, M. T. (2017). Association of microvascular dysfunction with late-life depression: A systematic review and meta-analysis. JAMA Psychiatry, 74(7), 729–739. https://doi.org/10.1001/jamapsychiatry.2017.0984
   PubMed Web of Science ®Google Scholar
• Vancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014). Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables. Psychological Medicine, 44(10), 2017–2028. https://doi.org/10.1017/S0033291713002778
   PubMed Web of Science ®Google Scholar
• Vancampfort, D., Firth, J., Schuch, F. B., Rosenbaum, S., Mugisha, J., Hallgren, M., Probst, M., Ward, P. B., Gaughran, F., De Hert, M., Carvalho, A. F., & Stubbs, B. (2017). Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: A global systematic review and meta-analysis. World Psychiatry, 16(3), 308–315. https://doi.org/10.1002/wps.20458
   PubMed Web of Science ®Google Scholar
• Vieira-Silva, S., Falony, G., Belda, E., Nielsen, T., Aron-Wisnewsky, J., Chakaroun, R., Forslund, S. K., Assmann, K., Valles-Colomer, M., Nguyen, T. T. D., Proost, S., Prifti, E., Tremaroli, V., Pons, N., Le Chatelier, E., Andreelli, F., Bastard, J.-P., Coelho, L. P., Galleron, N., … Raes, J. (2020). Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 581(7808), 310–315. https://doi.org/10.1038/s41586-020-2269-x
   PubMed Web of Science ®Google Scholar
• Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., Williams, L. J., Eyre, H. A., Kim, S. W., Zoungas, S., Carvalho, A. F., & Berk, M. (2021). Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neuroscience and Biobehavioral Reviews, 128, 693–708. https://doi.org/10.1016/j.neubiorev.2021.07.012
   PubMed Web of Science ®Google Scholar
• Wang, Q., Zengin, A., Deng, C., Li, Y., Newell, K. A., Yang, G. Y., Lu, Y., Wilder-Smith, E. P., Zhao, H., & Huang, X. F. (2009). High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Experimental Neurology, 216(1), 132–138. https://doi.org/10.1016/j.expneurol.2008.11.016
   PubMed Web of Science ®Google Scholar
• Wee, H.-Y., Ho, C.-H., Fu  , Liang, W., Hsieh, K.-Y., Wang, C.-C., Wang, J.-J., Chio, C.-C., Chang, C.-H., & Kuo, J.-R. (2016). Increased risk of new-onset depression in patients with traumatic brain injury and hyperlipidemia: The important role of statin medications. The Journal of Clinical Psychiatry, 77(4), 505–511. https://doi.org/10.4088/JCP.14m09749
   PubMed Web of Science ®Google Scholar
• Weye, N., Momen, N. C., Christensen, M. K., Iburg, K. M., Dalsgaard, S., Laursen, T. M., Mortensen, P. B., Santomauro, D. F., Scott, J. G., Whiteford, H. A., McGrath, J. J., & Plana-Ripoll, O. (2020). Association of specific mental disorders with premature mortality in the Danish population using alternative measurement methods. JAMA Network Open, 3(6), e206646. https://doi.org/10.1001/jamanetworkopen.2020.6646
   PubMed Web of Science ®Google Scholar
• Williams, L. J., Pasco, J. A., Mohebbi, M., Jacka, F. N., Stuart, A. L., Venugopal, K., O’Neil, A., & Berk, M. (2016). Statin and aspirin use and the risk of mood disorders among men. International Journal of Neuropsychopharmacology, 19(6), pyw008. https://doi.org/10.1093/ijnp/pyw008
   PubMed Web of Science ®Google Scholar
• Wirleitner, B., Rudzite, V., Neurauter, G., Murr, C., Kalnins, U., Erglis, A., Trusinskis, K., & Fuchs, D. (2003). Immune activation and degradation of tryptophan in coronary heart disease. European Journal of Clinical Investigation, 33(7), 550–554. https://doi.org/10.1046/j.1365-2362.2003.01186.x
   PubMed Web of Science ®Google Scholar
• Wirleitner, B., Sperner-Unterweger, B., & Fuchs, D. (2004). Statins to reduce risk of depression. Journal of the American College of Cardiology, 43(6), 1132–1133. https://doi.org/10.1016/j.jacc.2003.12.029
   PubMed Web of Science ®Google Scholar
• Wium-Andersen, I. K., Wium-Andersen, M. K., Jørgensen, M. B., & Osler, M. (2017a). Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients. Journal of Psychiatry & Neuroscience, 42(5), 320–330. https://doi.org/10.1503/jpn160244
   PubMed Web of Science ®Google Scholar
• Wium-Andersen, I. K., Wium-Andersen, M. K., Jørgensen, M. B., & Osler, M. (2017b). Anti-inflammatory treatment and risk of depression in 91,842 patients with acute coronary syndrome and 91,860 individuals without acute coronary syndrome in Denmark. International Journal of Cardiology, 246, 1–6. https://doi.org/10.1016/j.ijcard.2017.05.105
   PubMed Web of Science ®Google Scholar
• Wu, H., Lv, W., Pan, Q., Kalavagunta, P. K., Liu, Q., Qin, G., Cai, M., Zhou, L., Wang, T., Xia, Z., & Shang, J. (2019). Simvastatin therapy in adolescent mice attenuates HFD-induced depression-like behavior by reducing hippocampal neuroinflammation. Journal of Affective Disorders, 243, 83–95. https://doi.org/10.1016/j.jad.2018.09.022
   PubMed Web of Science ®Google Scholar
• Wu, S., Ding, Y., Wu, F., Xie, G., Hou, J., & Mao, P. (2016). Serum lipid levels and suicidality: A meta-analysis of 65 epidemiological studies. Journal of Psychiatry & Neuroscience, 41(1), 56–69. https://doi.org/10.1503/jpn.150079
   PubMed Web of Science ®Google Scholar
• Yan, J., Xu, Y., Zhu, C., Zhang, L., Wu, A., Yang, Y., Xiong, Z., Deng, C., Huang, X. F., Yenari, M. A., Yang, Y. G., Ying, W., & Wang, Q. (2011). Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: The association with anti-inflammatory responses. PLOS One, 6(6), e20945. https://doi.org/10.1371/journal.pone.0020945
   PubMed Web of Science ®Google Scholar
• Yang, C.-C., Jick, S. S., & Jick, H. (2003). Lipid-lowering drugs and the risk of depression and suicidal behavior. (Vol. 163, pp. 1926): American Medical Association.
   Google Scholar
• Yatham, M. S., Yatham, K. S., Ravindran, A. V., & Sullivan, F. (2019). Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. Journal of Affective Disorders, 257, 55–63. https://doi.org/10.1016/j.jad.2019.07.002
   PubMed Web of Science ®Google Scholar
• Yebyo, H. G., Aschmann, H. E., & Puhan, M. A. (2019). Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: A modeling study. Annals of Internal Medicine, 170(1), 1–10. https://doi.org/10.7326/m18-1279
   PubMed Web of Science ®Google Scholar
• Yu, D., & Liao, J. K. (2022). Emerging views of statin pleiotropy and cholesterol lowering. Cardiovascular Research, 118(2), 413–423. https://doi.org/10.1093/cvr/cvab032
   PubMed Web of Science ®Google Scholar
• Yu, X.-B., Zhang, H.-N., Dai, Y., Zhou, Z.-Y., Xu, R-a., Hu, L.-F., Zhang, C.-H., Xu, H.-Q., An, Y.-Q., Tang, C.-R., & Lin, G.-Y. (2019). Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. Journal of Affective Disorders, 245, 939–949. https://doi.org/10.1016/j.jad.2018.11.086
   PubMed Web of Science ®Google Scholar
• Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801–811. https://doi.org/10.1038/mp.2017.255
   PubMed Web of Science ®Google Scholar
• Zeiser, R. (2018). Immune modulatory effects of statins. Immunology, 154(1), 69–75. https://doi.org/10.1111/imm.12902
   PubMed Web of Science ®Google Scholar
• Zhang, H. N., Xu, H., Yu, X. B., Wang, C. Z., Xu, Q. Q., Dai, G. X., Hu, L. F., & Zhang, X. H. (2017). Effect of simvastatin on lipopolysaccharides induced depressive behaviors and neuroinflammation in mice. Chinese Pharmacological Bulletin, 33(3), 373–378. https://doi.org/10.3969/j.issn.1001-1978.2017.03.016
   Google Scholar
• Zhang, L., Bao, Y., Tao, S., Zhao, Y., & Liu, M. (2022). The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacological Research. 175, 106024. https://doi.org/10.1016/j.phrs.2021.106024
   PubMed Web of Science ®Google Scholar